Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 4, 2007, Pages

  Fülöp, Norbert ^a   Mason, Meredith M ^b   Dutta, Kaushik ^b   Wang, Peipei ^a   Davidoff, Amy J ^b   Marchase, Richard B ^c   Chatham, John C ^a,c,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Hexosamine biosynthesis; O linked N acetylglucosamine transferase; Protein O glycosylation

Indexed keywords

ACETYLGLUCOSAMINIDASE; CALSEQUESTRIN; GLUCOSE; INSULIN; LEPTIN; N ACETYLGLUCOSAMINE; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

ACETYLGLUCOSAMINE; AGING; ANIMALS; BIOMECHANICS; CALCIUM; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION; HYPERGLYCEMIA; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; N-ACETYLGLUCOSAMINYLTRANSFERASES; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

RATTUS;

EID: 34247336440     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00422.2006     Document Type: Article

References (42)

1. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53: 3201-3208, 2004.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
3. Buse MG, Robinson KA, Gettys TW, McMahon EG, Gulve EA. Increased activity of the hexosamine synthesis pathway in muscles of insulin-resistant ob/ob mice. Am J Physiol Endocrinol Metab 272: E1080-E1088, 1997.
4. Champattanachai V, Chatham JC, Marchase RB. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am J Physiol Cell Physiol 292: C178-C187, 2007.
5. Chatham JC, Forder JR, McNeill JH. The Heart in Diabetes. Norwell, MA: Kluwer Academic, 1996.
6. Cieniewski-Bernard C, Mounier Y, Michalski JC, Bastide B. OG1cNAc level variations are associated with the development of skeletal muscle atrophy. J Appl Physiol 100: 1499-1505, 2006.
7. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278: 44230-44237, 2003.
8. Dillmann WH. Diabetes mellitus and hypothyroidism induce changes in myosin isoenzyme distribution in the rat heart-do alterations in fuel flux mediate these changes? Adv Exp Med Biol 194: 469-479, 1986.
9. Dutta K, Carmody MW, Cala SE, Davidoff AJ. Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J Mol Cell Cardiol 34: 985-996, 2002.
10. Dutta K, Podolin DA, Davidson MB, Davidoff AJ. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50: 1186-1192, 2001.
11. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham heart study). Am J Cardiol 68: 85-89, 1991.
12. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population. Diabetes 23: 105-111, 1974.
13. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, Taegtmeyer H. Activation of PPARγ enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 289: E328-E336, 2005.
14. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshijima M, Dillmann WH. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 96: 1006-1013, 2005.
15. Lefebvre T, Ferreira S, Dupont-Wallois L, Bussiere T, Dupire MJ, Delacourte A, Michalski JC, and Caillet-Boudin ML. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins - a role in nuclear localization. Biochim Biophys Acta 1619: 167-176, 2003.
16. 2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49: 1434-1446, 2006.
17. Liu J, Pang Y, Chang T, Bounelis P, Chatham JC, Marchase RB. Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J Mol Cell Cardiol 40: 303-312, 2006.
18. Liu K, Paterson AJ, Zhang F, McAndrew J, Fukuchi K, Wyss JM, Peng L, Hu Y, Kudlow JE. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem 89: 1044-1055, 2004.
19. Liu P, Xu B, Cavalieri TA, Hock CE. Age-related difference in myocardial function and inflammation in a rat model of myocardial ischemia-reperfusion. Cardiovasc Res 56: 443-453, 2002.
20. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the "O-GlcNAc code." Sci STKE 2005: re13, 2005.
21. 2+ elevation in neonatal cardiomyocytes via protein-associated O-linked N-acetylglucosamine. Am J Physiol Cell Physiol 290: C57-C65, 2006.
22. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 36: 501-505, 2000.
23. Oh-Ishi M, Maeda T. Separation techniques for high-molecular-mass proteins. J Chromatogr B Analyt Technol Biomed Life Sci 771: 49-66, 2002.
24. Pang Y, Bounelis P, Chatham JC, Marchase RB. The hexosamine pathway is responsible for the inhibition by diabetes of phenylephrineinduced inotropy. Diabetes 53: 1074-1081, 2004.
25. i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55: 608-615, 2006.
26. Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34: 1425-1431, 2002.
27. Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol Heart Circ Physiol 272: H148-H158, 1997.
28. Ren J, Gintant GA, Miller RE, Davidoff AJ. High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol Heart Circ Physiol 273: H2876-H2883, 1997.
29. Ren J, Sowers JR, Walsh MF, Brown RA. Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol 279: H1708-H1714, 2000.
30. Rex-Mathes M, Werner S, Strutas D, Griffith LS, Viebahn C, Thelen K, Schmitz B. O-GlcNAc expression in developing and ageing mouse brain. Biochimie 83: 583-590, 2001.
31. Robinson KA, Weinstein ML, Lindenmayer GE, Buse MG. Effects of diabetes and hyperglycemia on the hexosamine synthesis pathway in rat muscle and liver. Diabetes 44: 1438-1446, 1995.
32. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 26: 913-922, 1992.
33. Schwanke ML, Dutta K, Podolin DA, Davidoff AJ. Cardiomyocyte dysfunction in insulin-resistant rats: a female advantage. Diabetologia 49: 1097-1105, 2006.
34. Slawson C, Housley MP, Hart GW. O-GlcNAc cycling: how a single sugar post-translational modification is changing the way we think about signaling networks. J Cell Biochem 97: 71-83, 2006.
35. Wang P, Chatham JC. The onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 286: E725-E736, 2004.
36. Wang P, Lloyd SG, Zeng H, Bonen A, Chatham JC. The impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 288: H2102-H2110, 2005.
37. Weigert C, Klopfer K, Kausch C, Brodbeck K, Stumvoll M, Haring HU, Schleicher ED. Palmitate-induced activation of the hexosamine pathway in human myotubes: increased expression of glutamine:fructose-6-phosphate aminotransferase. Diabetes 52: 650-656, 2003.
38. Wold LE, Dutta K, Mason MM, Ren J, Cala SE, Schwanke ML, Davidoff AJ. Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J Mol Cell Cardiol 39: 297-307, 2005.
39. Yao PJ, Coleman PD. Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease. Neurosci Lett 252: 33-36, 1998.
40. Yao PJ, Coleman PD. Reduction of O-linked N-acetylglucosaminemodified assembly protein-3 in Alzheimer's disease. J Neurosci 18: 2399-2411, 1998.
41. Yki-Jarvinen H, Daniels MC, Virkamaki A, Makimattila S, DeFronzo RA, McClain D. Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45: 302-307, 1996.
42. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. OGlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115: 715-725, 2003.